This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical (APYX) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.
Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.
Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?
by Zacks Equity Research
Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.
Will Flagship Impella Drive ABIOMED's (ABMD) Q4 Earnings?
by Zacks Equity Research
ABIOMED's (ABMD) fourth-quarter results are likely to gain from flagship Impella despite foreign exchange headwinds.
DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Cardinal Health (CAH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $47.47, moving +1.32% from the previous trading session.
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) G6 censors and lucrative collaborations are likely to drive Q1 results.
BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q1 Earnings?
by Zacks Equity Research
Strength in PerkinElmer's (PKI) core Diagnostics business is expected to drive Q1 results amid foreign exchange woes.
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
What's in Store for Align Technology (ALGN) in Q1 Earnings?
by Zacks Equity Research
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
Varian Medical (VAR) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Varian Medical (VAR) expects to gain significantly from APAC and EMEA regions in fiscal Q2.
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
UnitedHealth (UNH) Q1 Earnings Beat Estimates, Guides Up
by Zacks Equity Research
UnitedHealth (UNH) Q1 earnings beat on higher revenues and membership.
Cardinal Health (CAH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $46.79 in the latest trading session, marking a +0.88% move from the prior day.
What's in the Store for UnitedHealth (UNH) Earnings in Q1?
by Zacks Equity Research
UnitedHealth (UNH) should gain from higher revenues, membership partly offset by rise in expenses.
Top Ranked Income Stocks to Buy for April 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 4th
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?
by Zacks Equity Research
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
CAH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?